Valeant partner Cosmo turns wannabe IBS-D rival, and it could do some sales damage: analyst

Valeant partners with Cosmo Pharmaceuticals on ulcerative colitis med Uceris. But in the irritable bowel syndrome arena, the two may soon be at odds—and one analyst thinks Wall Street is underestimating the toll that could take on the Canadian drugmaker.Original Article